O'Keefe Stevens Advisory’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.94M | Sell |
80,568
-2,611
| -3% | -$68.3K | 0.4% | 29 |
|
|
2026
Q1 | $2.34M | Buy |
83,179
+3,932
| +5% | +$105K | 0.58% | 26 |
|
|
2025
Q4 | $1.97M | Sell |
79,247
-13,961
| -15% | -$352K | 0.51% | 26 |
|
|
2025
Q3 | $2.37M | Sell |
93,208
-9,096
| -9% | -$225K | 0.64% | 25 |
|
|
2025
Q2 | $2.48M | Buy |
102,304
+4,245
| +4% | +$99K | 0.7% | 26 |
|
|
2025
Q1 | $2.48M | Buy |
98,059
+2,181
| +2% | +$57.1K | 0.81% | 25 |
|
|
2024
Q4 | $2.54M | Buy |
95,878
+31,010
| +48% | +$841K | 0.79% | 26 |
|
|
2024
Q3 | $1.88M | Buy |
64,868
+12,567
| +24% | +$367K | 0.57% | 27 |
|
|
2024
Q2 | $1.46M | Buy |
52,301
+26,724
| +104% | +$736K | 0.49% | 28 |
|
|
2024
Q1 | $710K | Buy |
25,577
+10,143
| +66% | +$281K | 0.23% | 30 |
|
|
2023
Q4 | $444K | Buy |
15,434
+6,516
| +73% | +$197K | 0.18% | 34 |
|
|
2023
Q3 | $296K | Buy |
8,918
+813
| +10% | +$28.8K | 0.13% | 35 |
|
|
2023
Q2 | $297K | Buy |
8,105
+1,184
| +17% | +$46.1K | 0.13% | 36 |
|
|
2023
Q1 | $282K | Buy |
6,921
+846
| +14% | +$36.5K | 0.14% | 34 |
|
|
2022
Q4 | $311K | Hold |
6,075
| – | – | 0.18% | 33 |
|
|
2022
Q3 | $266K | Hold |
6,075
| – | – | 0.18% | 32 |
|
|
2022
Q2 | $319K | Hold |
6,075
| – | – | 0.2% | 32 |
|
|
2022
Q1 | $315K | Sell |
6,075
-100
| -2% | -$5.19K | 0.15% | 32 |
|
|
2021
Q4 | $365K | Hold |
6,175
| – | – | 0.17% | 32 |
|
|
2021
Q3 | $266K | Hold |
6,175
| – | – | 0.15% | 36 |
|
|
2021
Q2 | $242K | Hold |
6,175
| – | – | 0.13% | 35 |
|
|
2021
Q1 | $222K | Hold |
6,175
| – | – | 0.14% | 34 |
|
|
2020
Q4 | $227K | Sell |
6,175
-333
| -5% | -$12.2K | 0.16% | 37 |
|
|
2020
Q3 | $227K | Hold |
6,508
| – | – | 0.18% | 37 |
|
|
2020
Q2 | $202K | Buy |
+6,508
| New | +$221K | 0.17% | 36 |
|
|
2019
Q4 | $240K | Hold |
6,508
| – | – | 0.18% | 37 |
|
|
2019
Q3 | $222K | Hold |
6,508
| – | – | 0.17% | 39 |
|
|
2019
Q2 | $268K | Hold |
6,508
| – | – | 0.2% | 37 |
|
|
2019
Q1 | $262K | Hold |
6,508
| – | – | 0.2% | 35 |
|
|
2018
Q4 | $270K | Hold |
6,508
| – | – | 0.24% | 34 |
|
|
2018
Q3 | $272K | Hold |
6,508
| – | – | 0.19% | 35 |
|
|
2018
Q2 | $224K | Sell |
6,508
-159
| -2% | -$5.43K | 0.18% | 36 |
|
|
2018
Q1 | $224K | Buy |
6,667
+633
| +10% | +$21.8K | 0.2% | 43 |
|
|
2017
Q4 | $207K | Buy |
+6,034
| New | +$206K | 0.19% | 42 |
|
Other funds holding PFE
O'Keefe Stevens Advisory's PFE Position: Q2 2026 in Review
O'Keefe Stevens Advisory reduced its Pfizer (PFE) stake by 3.1% in Q2 2026, selling an estimated $68.3K and leaving 80,568 shares worth $1.94M. The position accounts for 0.4% of the portfolio, ranked #29.
O'Keefe Stevens Advisory first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.54M in Q4 2024. 2,831 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- O'Keefe Stevens Advisory held 80,568 shares of Pfizer worth $1.94M as of Q2 2026.
- O'Keefe Stevens Advisory sold 2,611 Pfizer shares in Q2 2026, an estimated $68.3K.
- Pfizer made up 0.4% of O'Keefe Stevens Advisory's portfolio in Q2 2026, its #29 holding.
- O'Keefe Stevens Advisory first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
- O'Keefe Stevens Advisory's Pfizer position peaked at $2.54M in Q4 2024.
- 2,831 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on O'Keefe Stevens Advisory's 13F filing for Q2 2026, filed 13 Jul 2026.